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 Purpose: The identification and quantification of protein expression levels of nutlin-3A-induced p53 stabilization and activation in human lymphoma.
Methods: The Isotope Coded Protein Label (ICPL) technique was followed by nano-Liquid Chromatography coupled on-line with Mass Spectrometry (nLC-MS/MS).
 Results: Reliable identification & differential quantitative determination of human lymphoma proteome profile, revealing alterations in the HSPs relative expression levels.
Overview 
Introduction 
 p53, a master tumor suppressor gene is impaired in >50% of all
human cancers [1]. However, >80% of haematological malignancies
express wt p53, including Hodgkin’s (HL) and Non-Hodgkin’s
lymphomas (NHL).
MDM2 (HDM2 in humans) binds to wt p53 and negatively modulates its
transcriptional activity and stability [2].
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 ICPL approach coupled with 1D-SDS-PAGE & nLC-MS/MS was applied for a large-scale proteomics analysis of 3 types of human lymphoma, providing successful identification & relative
quantitation of differentially expressed proteins.
Our findings provide important advances in understanding the biology of nutlin-3A treatment in wt p53 lymphoma cells, demonstrating substantial decrease in HSPs levels .
This study stresses out the biological similarities as well as differences between HL, MCL & ALCL. Further data processing will uncover far more comprehensive & thorough information on
the participating pathways in haematological malignancies.
Validation studies using genetic approaches are being performed, confirming a selection of abundantly expressed proteins of interest.
Conclusions – Future Plans
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Protein Comparison in the 6 Different Lymphoma Cell Lines (HL & NHL)
 Nutlin-3A, an MDM2-antagonist, induces stabilization and reactivation of the wt p53
pathway in cancer cells, followed by the infliction of cell cycle arrest and apoptosis
[3].
 Scope of the study is the mode of action of nutlin-3A-mediated wt p53 stabilization
and reactivation, in human cell lines of HL (2) and NHL, Anaplastic Large Cell
Lymphoma (ALCL, 2) and Mantle Cell Lymphoma (MCL, 2).
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